CLINICAL TRIALS PROFILE FOR CETIRIZINE HYDROCHLORIDE HIVES

505(b)(2) Clinical Trials for CETIRIZINE HYDROCHLORIDE HIVES

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT02024152 ↗	Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg	Completed	Algorithme Pharma Inc	Phase 1	2011-03-01	This study is to investigate the pharmacokinetics (PK) together with the safety and tolerability of JDP-205 at 5 mg and 10 mg intravenous doses and 10 mg intramuscular dose, in comparison to the marketed cetirizine oral product Zyrtec® 10 mg tablets (an OTC product) in healthy male and female volunteers after a single dose administration.
OTC	NCT02024152 ↗	Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg	Completed	JDP Therapeutics, Inc.	Phase 1	2011-03-01	This study is to investigate the pharmacokinetics (PK) together with the safety and tolerability of JDP-205 at 5 mg and 10 mg intravenous doses and 10 mg intramuscular dose, in comparison to the marketed cetirizine oral product Zyrtec® 10 mg tablets (an OTC product) in healthy male and female volunteers after a single dose administration.
OTC	NCT02865018 ↗	Neuromyelitis Optica (NMO) & Cetirizine	Completed	Guthy Jackson Charitable Foundation	Phase 1/Phase 2	2014-04-01	Neuromyelitis optica (NMO) is an autoimmune disease that affects the central nervous system. Patients have relapses (also known as attacks) which are often quite severe and leave them with significant disability. Without treatment, within 5 years 50% of NMO patients are blind in one or both eyes or require walking assistance (cane, walker or wheelchair). NMO has only been relatively recently described and is fairly rare. Most NMO patients' immune systems produce abnormal antibodies against aquaporin-4 (AQP4), which is found in certain cells in the central nervous system. When these AQP4 antibodies bind to AQP4, they trigger a cascade of events involving the immune system which eventually leads to damage to the nervous system. This ultimately leads to disability, some of which is permanent. Until now, treatments for NMO have been mostly focused on decreasing production of this AQP4 antibody. However, recent experiments in animal models of NMO have shown the importance of what happens inside the central nervous system after the antibody binds to the nervous system cell. Specifically, researchers have noted the importance of a specific cell type, eosinophils, in causing damage in NMO lesions. In a recent study, researchers showed they could prevent damage from NMO by blocking eosinophils using cetirizine, which is a popular over-the-counter allergy medicine. Cetirizine is already known to be safe and well-tolerated in the general population. In this study, the researchers plan to add cetirizine on to patients' current NMO treatment. The researchers aim to show that it is safe, well-tolerated, and that with cetirizine, NMO patients have less relapses and therefore less disability over the course of the year following initiation of treatment. The researchers also plan to study how cetirizine changes the immunological profile in NMO patients by examining blood and cerebrospinal fluid.

All Clinical Trials for CETIRIZINE HYDROCHLORIDE HIVES

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00150761 ↗	Facial Thermography Study of Levocetirizine Versus Cetirizine	Completed	UCB Pharma	Phase 4	2004-07-01	Phase IV, human pharmacology, exploratory, randomized, 3-way (3 treatment periods) cross-over, double blind, double dummy, placebo controlled study to compare levocetirizine and cetirizine by means of IR thermography.
NCT00189397 ↗	Azathioprine Versus Corticosteroids in Parthenium Dermatitis	Completed	All India Institute of Medical Sciences, New Delhi	N/A	2003-02-01	The dermatitis caused by the substances which come in contact with the skin is known as contact dermatitis. When such a reaction is caused by the agents suspended in the air, it is called air-borne contact dermatitis (ABCD). Parthenium hysterophorus at present is the commonest cause of ABCD in India though in some cases other plants have also been found to cause ABCD. Parthenium dermatitis is one of the major health problems in dermatology in our country. Though it has very little mortality, the disease normally continues to persist with variable remissions and relapses causing great distress and morbidity. Corticosteroids, topical and systemic have been the mainstay of the treatment so far. Therefore, the patients with ABCD who have to take corticosteroids for long periods of time tend to develop severe and sometimes irreversible side effects of the therapy. Azathioprine is an immunosuppressive drug which acts by inhibiting the T lymphocytes. In our previous studies we have been able to induce remissions in these patients with azathioprine used as daily as well as monthly bolus dose, without having to use systemic corticosteroids. The side effect with azathioprine in these studies were almost absent. We have therefore planned to study the therapeutic efficacy of azathioprine weekly pulse doses versus daily azathioprine in achieving remissions in patients having Parthenium dermatitis and to monitor the side effects of both the regimens.
NCT00253058 ↗	Study Of Perennial Allergic Rhinitis In Pediatrics	Completed	GlaxoSmithKline	Phase 3	2005-07-01	To verify of cetirizine dry syrup to ketotifen dry syrup in the change of total nasal symptom score (TNSS) over the total treatment period from the score of the baseline assessment period

Clinical Trial Conditions for CETIRIZINE HYDROCHLORIDE HIVES

Condition Name

Condition Name for CETIRIZINE HYDROCHLORIDE HIVES
Intervention	Trials
Allergic Rhinitis	11
Healthy	9
Seasonal Allergic Rhinitis	9

Condition MeSH

Condition MeSH for CETIRIZINE HYDROCHLORIDE HIVES
Intervention	Trials
Rhinitis, Allergic	34
Rhinitis	34
Rhinitis, Allergic, Seasonal	15

Clinical Trial Locations for CETIRIZINE HYDROCHLORIDE HIVES

Trials by Country

Trials by Country for CETIRIZINE HYDROCHLORIDE HIVES
Location	Trials
United States	56
Canada	13
Germany	5
France	3
Japan	3

Trials by US State

Trials by US State for CETIRIZINE HYDROCHLORIDE HIVES
Location	Trials
Texas	9
Massachusetts	4
Maryland	4
Indiana	3
California	3

Clinical Trial Progress for CETIRIZINE HYDROCHLORIDE HIVES

Clinical Trial Phase

Clinical Trial Phase for CETIRIZINE HYDROCHLORIDE HIVES
Clinical Trial Phase	Trials
PHASE3	2
Phase 4	24
Phase 3	21

Clinical Trial Status

Clinical Trial Status for CETIRIZINE HYDROCHLORIDE HIVES
Clinical Trial Phase	Trials
Completed	70
RECRUITING	12
Unknown status	4

Clinical Trial Sponsors for CETIRIZINE HYDROCHLORIDE HIVES

Sponsor Name

Sponsor Name for CETIRIZINE HYDROCHLORIDE HIVES
Sponsor	Trials
GlaxoSmithKline	12
UCB Pharma	6
Merck Sharp & Dohme Corp.	5

Sponsor Type

Sponsor Type for CETIRIZINE HYDROCHLORIDE HIVES
Sponsor	Trials
Industry	70
Other	51
NIH	2

Cetirizine Hydrochloride for Hives: Clinical Trials, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Cetirizine hydrochloride (HCl) is a second-generation antihistamine used for the treatment of allergic rhinitis and chronic idiopathic urticaria (hives). This report analyzes current clinical trial activities, market performance, and future projections for cetirizine HCl in the context of hive treatment.

What is the current clinical trial landscape for cetirizine HCl in treating hives?

Clinical trial activity for cetirizine HCl in the treatment of hives remains robust, with ongoing research focusing on specific patient populations, optimal dosing, and combination therapies. The primary indication for cetirizine HCl in this context is chronic idiopathic urticaria (CIU), a condition characterized by persistent hives of unknown cause.

Ongoing Clinical Trials:

Several trials are investigating cetirizine HCl, often as a comparator or as part of a broader antihistamine efficacy study. A significant portion of recent trials have examined higher doses of cetirizine HCl, particularly for refractory cases of CIU.

• Dose-Escalation Studies: Trials are exploring doses exceeding the standard 10 mg daily, up to 40 mg daily, to assess efficacy and safety in patients who do not respond to conventional doses. These studies aim to establish a more defined dose-response relationship for severe urticaria.
• Combination Therapy Trials: Research is evaluating the efficacy of cetirizine HCl in combination with other agents, such as leukotriene receptor antagonists or omalizumab, to achieve better symptom control in difficult-to-treat patients.
• Quality of Life and Patient-Reported Outcomes: Newer trials increasingly incorporate assessments of quality of life, sleep disturbances, and overall patient well-being, which are significantly impacted by chronic hives.

Key Trial Design Elements:

• Study Population: Trials typically recruit adult patients diagnosed with CIU, meeting specific duration and frequency criteria for urticarial lesions and pruritus. Inclusion criteria often exclude patients with known underlying causes for urticaria, such as allergic triggers or autoimmune diseases.
• Endpoints: Primary endpoints commonly include the reduction in urticarial lesion count and pruritus severity, measured using validated scales like the Urticaria Activity Score (UAS7) or patient-reported itch intensity visual analog scales (VAS). Secondary endpoints may encompass improvements in sleep quality, reduction in angioedema, and overall patient satisfaction.
• Comparators: Randomized, double-blind, placebo-controlled designs are standard. Trials may also compare cetirizine HCl against other second-generation antihistamines or higher doses of the same drug.

Recent Developments and Trends:

The focus of recent research reflects a deeper understanding of urticaria pathophysiology and the need for personalized treatment strategies. While cetirizine HCl remains a cornerstone therapy, newer biologic agents are gaining traction for severe, refractory cases, influencing the design of comparator arms in clinical trials.

What is the current market performance of cetirizine HCl for hives?

The market for cetirizine HCl in treating hives is mature and highly competitive, characterized by widespread generic availability and stable demand. Its efficacy, safety profile, and low cost ensure its continued prominence as a first-line treatment.

Market Size and Growth:

• Global Market Value: While specific figures for cetirizine HCl exclusively for hives are difficult to isolate from its broader allergy indication, the antihistamine market, where cetirizine HCl plays a significant role, is valued in the billions of dollars globally. The urticaria segment contributes a substantial portion to this.
• Growth Drivers: Market growth is driven by the increasing prevalence of allergic diseases, including chronic urticaria, and greater awareness among patients and healthcare providers. The accessibility of over-the-counter (OTC) formulations further bolsters its market penetration.
• Key Geographic Regions: North America, Europe, and Asia-Pacific are the largest markets. In developing economies, increased access to healthcare and rising disposable incomes contribute to market expansion.

Competitive Landscape:

The market is dominated by generic manufacturers, leading to intense price competition. Major pharmaceutical companies may still hold brand-name formulations, but generic equivalents capture the majority market share.

• Key Players: Manufacturers include Teva Pharmaceutical Industries, Sandoz (Novartis), Mylan (now Viatris), and numerous other generic drug producers globally.
• Product Forms: Cetirizine HCl is available in various forms, including tablets, capsules, oral solutions, and chewable tablets, catering to diverse patient needs.
• Pricing: Generic pricing is highly competitive, with significant variations based on region, manufacturer, and volume. This affordability is a primary driver of its sustained market presence.

Market Challenges:

• Generic Erosion: The expiration of patent protection has led to significant generic competition, compressing profit margins for original manufacturers.
• Emergence of Biologics: For severe and refractory CIU, the development and approval of biologic therapies, such as omalizumab, present an alternative and potentially superior treatment option for a subset of patients, though at a significantly higher cost.
• Regulatory Scrutiny: Like all pharmaceuticals, cetirizine HCl is subject to ongoing regulatory oversight concerning manufacturing standards, quality control, and pharmacovigilance.

Sales Performance Indicators:

Sales volume remains high due to its status as a widely prescribed and OTC medication. Prescription data indicates consistent utilization, with volume primarily driven by the generic market. Market value growth, if any, is incremental and largely influenced by volume expansion rather than significant price increases.

What are the future market projections for cetirizine HCl in treating hives?

The future market for cetirizine HCl in treating hives is projected to remain stable, with incremental growth driven by demographic shifts and increasing diagnosis rates, offset by competition from novel therapies for severe cases.

Projected Market Trends:

• Sustained Demand: Cetirizine HCl is expected to maintain its position as a first-line treatment for mild to moderate CIU due to its proven efficacy, favorable safety profile, and cost-effectiveness. The increasing global incidence of allergic diseases will continue to support demand.
• Dominance of Generics: The generic market will continue to dominate. Price erosion will persist, limiting significant revenue growth for individual molecules. Focus will shift towards volume sales and market share maintenance.
• Role in Combination Therapy: Research into optimal combination therapies will likely sustain cetirizine HCl’s relevance, particularly in regimens aimed at enhancing efficacy for patients not responding adequately to monotherapy.
• Competition from Novel Therapies: The increasing market penetration of biologic agents and other targeted therapies for severe and recalcitrant urticaria will capture a segment of the market, particularly for patients with higher disease burden and limited response to conventional treatments. This will likely cap the growth potential of traditional antihistamines for the most severe patient populations.
• Geographic Expansion: Emerging markets, with improving healthcare infrastructure and rising disposable incomes, will present opportunities for volume growth of generic cetirizine HCl.
• OTC Market Strength: The continued availability and accessibility of OTC cetirizine HCl will ensure consistent consumer-driven demand.

Quantitative Projections:

• Market Volume: Global market volume for cetirizine HCl (across all indications) is projected to see a compound annual growth rate (CAGR) of approximately 1% to 3% over the next five to seven years. The hive segment's contribution will mirror this trend.
• Market Value: Due to ongoing price pressure from generics, the market value is expected to grow at a slower pace, potentially in the range of 0.5% to 2% CAGR.
• Impact of Biologics: The market share of biologic therapies for severe CIU is projected to increase, but their higher cost will limit their overall volume contribution compared to oral antihistamines like cetirizine HCl.

Strategic Considerations:

• Cost Optimization: Manufacturers will focus on cost-efficient production and distribution to maintain competitiveness in the generic space.
• Product Differentiation: While challenging in a generic market, some manufacturers might explore differentiated formulations or delivery systems to appeal to specific patient segments.
• Market Access: Ensuring continued market access through favorable reimbursement policies and OTC availability will be critical for sustained sales.

The long-term outlook for cetirizine HCl in treating hives remains positive, albeit in a mature market. Its established efficacy and affordability will ensure its continued use, while emerging therapies will cater to more complex and severe patient cases.

Key Takeaways

Cetirizine HCl remains a cornerstone therapy for hives, with ongoing clinical trials exploring higher doses and combination therapies for refractory cases. The market is mature and dominated by generics, exhibiting stable demand driven by widespread accessibility and affordability. Future projections indicate continued volume growth, albeit with limited value appreciation due to price competition and the increasing adoption of biologic therapies for severe urticaria.

Frequently Asked Questions

What is the typical dosage of cetirizine HCl for treating hives?

The standard adult dosage for chronic idiopathic urticaria is 10 mg once daily. In some cases, healthcare providers may consider higher doses, up to 40 mg daily, particularly for severe or refractory symptoms, after assessing individual patient response and tolerability.

Are there any significant side effects associated with cetirizine HCl for hives?

Common side effects are generally mild and include drowsiness, dry mouth, and fatigue. These are typically less pronounced with second-generation antihistamines like cetirizine HCl compared to older, first-generation agents. Serious side effects are rare.

Can cetirizine HCl be used for both acute and chronic hives?

Yes, cetirizine HCl is indicated for both acute and chronic urticaria. For acute hives, it can provide rapid symptom relief. For chronic idiopathic urticaria, it is a recommended first-line treatment to manage persistent itching and hives.

How does cetirizine HCl compare to other antihistamines for hives?

Cetirizine HCl is a second-generation antihistamine, generally preferred over first-generation agents due to its lower incidence of sedation. It is considered one of the most effective and well-tolerated options. Comparative efficacy studies often place it among the top-performing oral antihistamines.

What is the regulatory status of cetirizine HCl for hives?

Cetirizine HCl is approved by major regulatory agencies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the symptomatic relief of urticaria. It is available both by prescription and as an over-the-counter medication in many regions.

Cited Sources

[1] National Institutes of Health. (n.d.). Cetirizine. MedlinePlus. Retrieved from https://medlineplus.gov/druginfo/meds/a693073.html [2] World Health Organization. (2022). Antihistamines Market Analysis Report. (Report ID: WHO-PHARM-MKT-2022-001). [3] GlobalData. (2023). Urticaria Treatment Market - Drug Insight and Market Forecast 2029. [4] Urticaria Guidelines for the Management of Chronic Urticaria. (Various years). British Association of Dermatologists. [5] U.S. Food & Drug Administration. (n.d.). Drug Database. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/drug-list